This article is more than 5 years old. Information may no longer be current.

OSN’s top stories of the week

Add topic to email alerts

Receive an email when new articles are posted on

Please provide your email address to receive an email when new articles are posted on .

Subscribe

Added to email alerts

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

Back to Healio

We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com.

Back to Healio

Here are the top five stories on Healio.com/OSN last week:

Bimatoprost sustained-release implant reduces IOP in phase 3 study

A bimatoprost sustained-release implant reduced IOP by approximately 30% over 12 weeks in a second phase 3 study. Read more.

Netarsudil ophthalmic solution shows positive phase 2 results in Japanese-American population

A pilot phase 2 trial showed Aerie Pharmaceuticals’ netarsudil ophthalmic solution lowered IOP in a Japanese-American population. Read more.

Takeda completes Shire acquisition

The deal was approved by 89.1% of Takeda’s shareholders and 99.8% of Shire’s shareholders. Read more.

Large data set correlates cholesterol levels with AMD

HDL cholesterol and triglycerides have, respectively, a positive and negative association with increased risk for age-related macular degeneration, particularly in the early stages. Read more.

Ocular Therapeutix submits supplemental NDA for Dextenza

A supplemental new drug application for Dextenza has been submitted to the FDA to expand its indication to include the treatment of ocular inflammation after ophthalmic surgery. Read more.